CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI
Identifieur interne : 003215 ( Main/Curation ); précédent : 003214; suivant : 003216CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI
Auteurs : J. Wirima [Malawi] ; M. E. Molyneux [Royaume-Uni] ; C. Khoromana [Royaume-Uni] ; H. M. Gilles [Royaume-Uni]Source :
- The Lancet [ 0140-6736 ] ; 1988.
English descriptors
- Teeft :
- Abdominal pain, Airway epithelium, American society, Arterial pressure, Cell count, Clinical trials, Comparable efficacy, Cure rate, Diluent solution, Dwangwa, Falciparum, Falciparum chloroquine, Falciparum malana, First part, First study, Frusemide, Haemoglobin level, Halofantrine, Halofantrine hydrochloride, Inhaled, Inhaled corticosteroids, Inhaled frusemide, Laboratory data, Lake malawi, Lung diseases, Malawi, Older children, Oral frusemide, Parasitaemia, Parasite, Parasite counts, Phenanthrene methanol compound halofantrine, Phenanthrene methanol halofantrine, Placebo, Plasmodium, Plasmodium falciparum, Protective effect, Pulse rate, Random order, Recrudescence rate, Resistant strains, Same time intervals, Second part, Second screening test, Second trial, Single dose, Study days, Tanzanian border, Tropical medicine, Typical history, West shore, Younger children.
Abstract
Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.
Url:
DOI: 10.1016/S0140-6736(88)92539-1
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A55
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000A55
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001F77
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003286
Links to Exploration step
ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title>
<author><name sortKey="Wirima, J" sort="Wirima, J" uniqKey="Wirima J" first="J." last="Wirima">J. Wirima</name>
</author>
<author><name sortKey="Molyneux, M E" sort="Molyneux, M E" uniqKey="Molyneux M" first="M. E." last="Molyneux">M. E. Molyneux</name>
</author>
<author><name sortKey="Khoromana, C" sort="Khoromana, C" uniqKey="Khoromana C" first="C." last="Khoromana">C. Khoromana</name>
</author>
<author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201</idno>
<date when="1988" year="1988">1988</date>
<idno type="doi">10.1016/S0140-6736(88)92539-1</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A55</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A55</idno>
<idno type="wicri:Area/Istex/Curation">000A55</idno>
<idno type="wicri:Area/Istex/Checkpoint">001F77</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F77</idno>
<idno type="wicri:doubleKey">0140-6736:1988:Wirima J:clinical:trials:with</idno>
<idno type="wicri:Area/Main/Merge">003286</idno>
<idno type="wicri:Area/Main/Curation">003215</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title>
<author><name sortKey="Wirima, J" sort="Wirima, J" uniqKey="Wirima J" first="J." last="Wirima">J. Wirima</name>
<affiliation wicri:level="1"><country xml:lang="fr">Malawi</country>
<wicri:regionArea>Kamuzu Central Hospital, Lilongwe, Malawi;</wicri:regionArea>
<wicri:noRegion>Malawi;</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Molyneux, M E" sort="Molyneux, M E" uniqKey="Molyneux M" first="M. E." last="Molyneux">M. E. Molyneux</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;</wicri:regionArea>
<wicri:noRegion>Liverpool;</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoromana, C" sort="Khoromana, C" uniqKey="Khoromana C" first="C." last="Khoromana">C. Khoromana</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;</wicri:regionArea>
<wicri:noRegion>Liverpool;</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool</wicri:regionArea>
<wicri:noRegion>Liverpool</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The Lancet</title>
<title level="j" type="abbrev">LANCET</title>
<idno type="ISSN">0140-6736</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1988">1988</date>
<biblScope unit="volume">332</biblScope>
<biblScope unit="issue">8605</biblScope>
<biblScope unit="page" from="250">250</biblScope>
<biblScope unit="page" to="252">252</biblScope>
</imprint>
<idno type="ISSN">0140-6736</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abdominal pain</term>
<term>Airway epithelium</term>
<term>American society</term>
<term>Arterial pressure</term>
<term>Cell count</term>
<term>Clinical trials</term>
<term>Comparable efficacy</term>
<term>Cure rate</term>
<term>Diluent solution</term>
<term>Dwangwa</term>
<term>Falciparum</term>
<term>Falciparum chloroquine</term>
<term>Falciparum malana</term>
<term>First part</term>
<term>First study</term>
<term>Frusemide</term>
<term>Haemoglobin level</term>
<term>Halofantrine</term>
<term>Halofantrine hydrochloride</term>
<term>Inhaled</term>
<term>Inhaled corticosteroids</term>
<term>Inhaled frusemide</term>
<term>Laboratory data</term>
<term>Lake malawi</term>
<term>Lung diseases</term>
<term>Malawi</term>
<term>Older children</term>
<term>Oral frusemide</term>
<term>Parasitaemia</term>
<term>Parasite</term>
<term>Parasite counts</term>
<term>Phenanthrene methanol compound halofantrine</term>
<term>Phenanthrene methanol halofantrine</term>
<term>Placebo</term>
<term>Plasmodium</term>
<term>Plasmodium falciparum</term>
<term>Protective effect</term>
<term>Pulse rate</term>
<term>Random order</term>
<term>Recrudescence rate</term>
<term>Resistant strains</term>
<term>Same time intervals</term>
<term>Second part</term>
<term>Second screening test</term>
<term>Second trial</term>
<term>Single dose</term>
<term>Study days</term>
<term>Tanzanian border</term>
<term>Tropical medicine</term>
<term>Typical history</term>
<term>West shore</term>
<term>Younger children</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201 |texte= CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI }}
This area was generated with Dilib version V0.6.33. |